Mallinckrodt will buy Maryland-based Sucampo Pharmaceuticals for about $840 million, the companies said, as the drug giant looks to diversify its portfolio after regulatory scrutiny has hurt its opioid sales.
from WSJ.com: US Business http://ift.tt/2lg027D
via IFTTT
No comments:
Post a Comment